{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:18:32Z","timestamp":1782512312661,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T00:00:00Z","timestamp":1522627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T00:00:00Z","timestamp":1522627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Abramson Center Support Grant","award":["P30-CA016520"],"award-info":[{"award-number":["P30-CA016520"]}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K23 CA141054"],"award-info":[{"award-number":["K23 CA141054"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["IRG-78-002-30"],"award-info":[{"award-number":["IRG-78-002-30"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"name":"When Everyone Survives Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10637-018-0585-x","type":"journal-article","created":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T01:44:47Z","timestamp":1522633487000},"page":"657-666","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition"],"prefix":"10.1007","volume":"36","author":[{"given":"Margaret T.","family":"Kasner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemarie","family":"Mick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace R.","family":"Jeschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Carabasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Filicko-O\u2019Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Flomenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle V.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth O.","family":"Hexner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina M.","family":"Luger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison W.","family":"Loren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K.","family":"Mangan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander E.","family":"Perl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,2]]},"reference":[{"issue":"18","key":"585_CR1","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1200\/JCO.2013.52.8562","volume":"32","author":"GJ Roboz","year":"2014","unstructured":"Roboz GJ, Rosenblat T, Arellano M, Gobbi M, Altman JK, Montesinos P, O\u2019Connell C, Solomon SR, Pigneux A, Vey N, Hills R et al. (2014) International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed\/refractory acute myeloid leukemia. J Clin Oncol 32(18):1919\u20131926","journal-title":"J Clin Oncol"},{"issue":"22","key":"585_CR2","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"T Ley","year":"2013","unstructured":"Ley T (2013) ea.: Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368(22):2059\u20132074","journal-title":"N Engl J Med"},{"issue":"23","key":"585_CR3","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G et al (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374(23):2209\u20132221","journal-title":"N Engl J Med"},{"issue":"13","key":"585_CR4","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1182\/blood-2004-11-4468","volume":"106","author":"Q Xu","year":"2005","unstructured":"Xu Q, Thompson JE, Carroll M (2005) Mtor regulates cell survival after etoposide treatment in primary aml cells. Blood 106(13):4261\u20134268","journal-title":"Blood"},{"issue":"6","key":"585_CR5","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2004-06-2494","volume":"105","author":"C Recher","year":"2005","unstructured":"Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM, Benzaquen D, Laurent G, Huguet F, Payrastre B (2005) Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105(6):2527\u20132534","journal-title":"Blood"},{"issue":"17","key":"585_CR6","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","volume":"12","author":"KW Yee","year":"2006","unstructured":"Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S et al (2006) Phase i\/ii study of the mammalian target of rapamycin inhibitor everolimus (rad001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12(17):5165\u20135173","journal-title":"Clin Cancer Res"},{"issue":"11","key":"585_CR7","doi-asserted-by":"crossref","first-page":"4523a","DOI":"10.1182\/blood.V104.11.4523.4523","volume":"104","author":"KWL Yee","year":"2004","unstructured":"Yee KWL, Garcia-Manero G, Thomas D, Ravandi-Kashani F, Verstovsek S, Andreeff M, Dancey JE, Giles FJ (2004) A phase ii study of temsirolimus (cci-779) in patients with advanced leukemias. Blood 104(11):4523a","journal-title":"Blood"},{"issue":"21","key":"585_CR8","doi-asserted-by":"publisher","first-page":"6732","DOI":"10.1158\/1078-0432.CCR-09-0842","volume":"15","author":"AE Perl","year":"2009","unstructured":"Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, Nasta SD et al (2009) A phase i study of the mammalian target of rapamycin inhibitor sirolimus and mec chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 15(21):6732\u20136739","journal-title":"Clin Cancer Res"},{"issue":"7","key":"585_CR9","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/leu.2013.17","volume":"27","author":"S Park","year":"2013","unstructured":"Park S, Chapuis N, Saint Marcoux F, Recher C, Prebet T, Chevallier P, Cahn JY, Leguay T, Bories P, Witz F, Lamy T et al. (2013) A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse. Leukemia 27(7):1479\u20131486","journal-title":"Leukemia"},{"issue":"2","key":"585_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1365-2141.2011.08940.x","volume":"156","author":"S Amadori","year":"2012","unstructured":"Amadori S, Stasi R, Martelli AM, Venditti A, Meloni G, Pane F, Martinelli G, Lunghi M, Pagano L, Cilloni D, Rossetti E et al (2012) Temsirolimus, an mtor inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: Results of a phase ii gimema study (aml-1107). Br J Haematol 156(2):205\u2013212","journal-title":"Br J Haematol"},{"issue":"6","key":"585_CR11","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1158\/1078-0432.CCR-11-2346","volume":"18","author":"AE Perl","year":"2012","unstructured":"Perl AE, Kasner MT, Shank D, Luger SM, Carroll M (2012) Single-cell pharmacodynamic monitoring of s6 ribosomal protein phosphorylation in aml blasts during a clinical trial combining the mtor inhibitor sirolimus and intensive chemotherapy. Clin Cancer Res: an official journal of the American Association for Cancer Research 18(6):1716\u20131725","journal-title":"Clin Cancer Res: an official journal of the American Association for Cancer Research"},{"issue":"1","key":"585_CR12","doi-asserted-by":"publisher","first-page":"e53292","DOI":"10.1371\/journal.pone.0053292","volume":"8","author":"S Loi","year":"2013","unstructured":"Loi S, Michiels S, Baselga J, Bartlett JM, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Dixon JM, Piccart MJ, Sotiriou C (2013) Pik3ca genotype and a pik3ca mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. PLoS One 8(1):e53292","journal-title":"PLoS One"},{"issue":"15","key":"585_CR13","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1182\/blood-2010-10-316224","volume":"117","author":"PG Woost","year":"2011","unstructured":"Woost PG, Solchaga LA, Meyerson HJ, Shankey TV, Goolsby CL, Jacobberger JW (2011) High-resolution kinetics of cytokine signaling in human cd34\/cd117-positive cells in unfractionated bone marrow. Blood 117(15):e131\u2013e141","journal-title":"Blood"},{"issue":"6","key":"585_CR14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5(6):649\u2013655","journal-title":"Am J Clin Oncol"},{"issue":"24","key":"585_CR15","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F et al (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21(24):4642\u20134649","journal-title":"J Clin Oncol"},{"issue":"4","key":"585_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343\u2013346","journal-title":"Control Clin Trials"},{"issue":"6","key":"585_CR17","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1200\/JCO.2004.07.048","volume":"22","author":"PL Greenberg","year":"2004","unstructured":"Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum B, Chin DL, Dewald G, Paietta E et al (2004) Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase iii trial (e2995). J Clin Oncol 22(6):1078\u20131086","journal-title":"J Clin Oncol"},{"issue":"9","key":"585_CR18","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.exphem.2006.05.002","volume":"34","author":"S Chow","year":"2006","unstructured":"Chow S, Minden MD, Hedley DW (2006) Constitutive phosphorylation of the s6 ribosomal protein via mtor and erk signaling in the peripheral blasts of acute leukemia patients. Exp Hematol 34(9):1183\u20131191","journal-title":"Exp Hematol"},{"key":"585_CR19","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1182\/blood.V124.21.3742.3742","volume":"124","author":"MR Litzow","year":"2014","unstructured":"Litzow MR, Wang XV, Carroll MP, Karp JE, Ketterling R, Kaufmann SH, Lazarus HM, Luger SM, Paietta EM, Rowe JM, Altman JK et al (2014) A randomized phase ii trial of three novel regimens for relapsed\/ refractory acute myeloid leukemia (aml) demonstrates encouraging results with a flavopiridol-based regimen: Results of eastern cooperative oncology group (ecog) trial e1906. Blood 124:3742\u20133742","journal-title":"Blood"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0585-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0585-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0585-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:23:13Z","timestamp":1678558993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0585-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,2]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["585"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0585-x","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,2]]},"assertion":[{"value":"23 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}